Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 86Kidney Neoplasms 25Neoplasms 24Breast Neoplasms 18Gastrointestinal Stromal Tumors 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 15Prostatic Neoplasms 8Urinary Bladder Neoplasms 7Brain Neoplasms 7Pancreatic Neoplasms 6Lung Neoplasms 6Colorectal Neoplasms 6Thyroid Neoplasms 5Stomach Neoplasms 5Solid Tumors 5Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Neuroendocrine Tumors 5Melanoma 5Glioblastoma 5Carcinoma 5Sarcoma 4Liver Neoplasms 4Esophageal Neoplasms 4Clear-cell metastatic renal cell carcinoma 4Carcinoma, Hepatocellular 4Astrocytoma 4Adenoma, Islet Cell 4Thyroid Cancer, Papillary 3

Interventions

rucaparib 1fludarabine 1Sunitinib 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy 1Paclitaxel 1Nivolumab 1Melphalan 1Erlotinib Hydrochloride 1Carboplatin 1Busulfan 1Bevacizumab 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma, Clear Cell × Sunitinib × Clear all
NCT01824615 2018-07-18

Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma

Cathay General Hospital

Phase 2 Completed
30 enrolled
Gynecologic

Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡